Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Affitech (Details)

v3.24.2.u1
Royalty and Commercial Payment Purchase Agreements - Affitech (Details) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Oct. 06, 2021
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Apr. 01, 2024
Agreements              
Payments of consideration under RPAs, AAAs and CPPAs       $ 37,000,000 $ 14,650,000    
Contingent consideration under RPAs, AAAs and CPPAs   $ 3,000,000   3,000,000   $ 7,000,000  
Receipts under RPAs, AAAs and CPPAs       16,741,000 $ 2,934,000    
Short-term royalty and commercial payment receivables   14,257,000   14,257,000   $ 14,215,000  
Income from purchased receivables under effective interest rate method, Short-Term       4,562,000      
Affitech              
Agreements              
Reduction in short-term royalty receivable balance due to receipt of payment       7,396,000      
Recognition of contingent consideration, Short-Term       3,000,000      
Income from purchased receivables under effective interest rate method, Short-Term       4,562,000      
Affitech | Commercial Payment Purchase Agreement              
Agreements              
Payments of consideration under RPAs, AAAs and CPPAs $ 6,000,000.0   $ 6,000,000.0        
Period from each royalty payment date payment is due           60 days  
Maximum regulatory and commercial sales milestone payments 20,000,000.0            
Acquisition of royalty and commercial payment receivables, Long-Term 14,000,000.0            
Maximum commercial sales milestone payments $ 12,000,000.0 3,000,000.0   3,000,000.0      
Recognition of contingent consideration, Short-Term       3,000,000.0      
Recognition of contingent consideration, Long-Term           $ 6,000,000.0  
Amount of allowance for credit losses   0   0   0  
Royalty and commercial payment receivable             $ 7,800,000
Income from purchased receivables under effective interest rate method, Short-Term   4,500,000   4,500,000      
Affitech | Commercial Payment Purchase Agreement | Faricimab (VABYSMO)              
Agreements              
Payments eligible to receive (as a percent) 0.50%            
Commercial payment receivable term 10 years            
Affitech | Commercial Payment Purchase Agreement | Regulatory milestones              
Agreements              
Contingent consideration under RPAs, AAAs and CPPAs $ 8,000,000.0            
Affitech | Commercial Payment Purchase Agreement | Sales-based milestones, first and second              
Agreements              
Contingent consideration under RPAs, AAAs and CPPAs   $ 0 0 $ 0   $ 6,000,000.0  
Affitech | Commercial Payment Purchase Agreement | Sales-based milestones, third              
Agreements              
Contingent consideration under RPAs, AAAs and CPPAs     3,000,000.0        
Short-term royalty and commercial payment receivables     $ 3,000,000.0